Back to search

Switzerland· 68135002

Tenkasi 1200 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

A oritavancin product containing oritavancinum, registered in Switzerland by A. Menarini GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC J01XA05

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTenkasi 1200 mg, Pulver für ein Konze…ATCJ01XA05REGISTER NO.68135002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Oritavancin is registered in 12 of 19 countries.

Countries holding a registration under ATC J01XA05 (oritavancin), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Oritavancin · ATC J01XA05

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
oritavancinum
Manufacturer
A. Menarini GmbH
Country
Switzerland (CH)
ATC code
J01XA05
ATC class
Oritavancin
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680681350026
    Durchstf 1 Stk
    CHF 2260.5

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

68 interactions on record for oritavancin.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Oritavancin · interactions on record

68 records

  • 2 severe
  • 64 moderate
  • 2 minor

Most severe, free to view

  • HeparinB01AB01severe
  • HeparinB05CX05severe
  • Sodium picosulfateA06AB08moderate
  • NitisinoneA16AX04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4e7e6dc2-63f2-46f5-a74a-57b14f8a917f
GET /v1/drugs/4e7e6dc2-63f2-46f5-a74a-57b14f8a917f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "oritavancinum 1200 mg",
  "valid_from": "2025-07-01",
  "limitations": "[{\"description\":\"Zur Behandlung akuter bakterieller Haut- und Weichgewebeinfektion (ABSSSI) bei Erwachsenen. Dies schliesst folgende Infektionsarten ein: Cellulitis/Erysipel, Wundinfektion oder grösserer kutaner Abszess, deren Erythem ≥ 75cm2 beträgt und ≥ 2 Zeichen einer systemischen Infektion\\nvorliegen. Die Behandlung mit TENKASI ist nur dann angezeigt, wenn die für die Initialbehandlung dieser Infektionen empfohlenen Antibiotika als nicht geeignet erachtet werden und wenn nach mikrobiologischer Sensibilitätsprüfung feststeht oder ein starker Verdacht besteht, dass die Infektion durch Methicillin-resistenten Staphylococcus aureus (MRSA) verursacht ist. Die allgemein anerkannten Richtlinien für den angemessenen Gebrauch von antimikrobiellen Wirkstoffen sind zu berücksichtigen. Die Indikationsstellung und die Verordnung von TENKASI darf nur im Spital unter Anleitung eines Infektiologen erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21404.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-07-01\"}]",
  "galenic_form": "Trockensub 1200 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2025-07-01",
  "self_retention_pct": 10
}

See everything about oritavancin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.